Navigation Links
HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China

SAN DIEGO, Nov. 9 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China. The agreement is another in a series of collaborations that HUYA has established with China's leading research and development institutions to enable and accelerate the global development and commercialization of novel biopharmaceutical product opportunities originating in China.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new pre-clinical and clinical stage compounds. The agreement with Ocean University of China provides HUYA with rights of first review and negotiation relating to certain novel therapeutic and diagnostic product candidates owned or controlled by the University. In return, Ocean University of China gains access to HUYA's global network of pharmaceutical partners and its expertise in pre-clinical and clinical development.

"Ocean University is one of China's leading institutions, with considerable expertise in the field of marine pharmaceutical science," said Michael Newman, Ph.D., Executive Vice President of Oncology at HUYA Bioscience. "We look forward to collaborating with this prestigious university to bring novel biopharmaceutical products to the global marketplace."

"Ocean University is committed to strengthening its research programs in marine pharmaceutical science," said Qiangming Wu, Ph.D., Executive Dean, School of Medicine and Pharmacy, Ocean University of China. "We are pleased to partner with HUYA's expert team to achieve this objective."


HUYA is the leader in global pharmaceutical co-development with China. With six strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach to pharmaceutical co-development between the U.S. and China. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at


Ocean University of China, located in Qingdao, is one of the top universities in China. It is considered a leader in research in the area of marine pharmaceutical science, and has received numerous awards for its work. The University has undertaken a large number of research papers and made great contributions to the construction of the marine-based economy of Shandong Province, including projects such as the seawater aquaculture. Ocean University has been ranked No. 8 in terms of the number of prizes won for science and technology advancement awarded by the Ministry of Education. For more information visit


    Bob Giargiari, MBA, EVP Finance & CFO
    HUYA Bioscience International, LLC
    (858) 798-8800

    Qing (Vicky) Xia, Scientific Research Manager
    HUYA Bioscience International, LLC
    86 (21) 51323312

    Media Contact:
    Juliet Travis
    (510) 452-3771

SOURCE HUYA Bioscience International

SOURCE HUYA Bioscience International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Professionals in bioscience, food-related industries turn to K-State
4. Aeon Bioscience Continues Development of Drug Eluting Stents
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
Post Your Comments:
(Date:11/26/2015)... (PRWEB) , ... November 26, ... ... online platform for mental health and wellness consultation, has collaborated with Women’s ... holistically address their reader’s queries on topics on mental and emotional well-being ...
(Date:11/25/2015)... ... ... The holiday season is jam-packed with family dinners, parties ... is of the utmost importance. Whether you are cooking at home for the ... try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever ... with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the ... the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... 25, 2015 , ... Wimbledon Health Partners, the industry leader ... Athletics Facebook page to educate the public, parents and school athletic departments ... people under the age of 25 die from sudden cardiac arrest every year. ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  The American Academy of Pediatrics (AAP), American ... March of Dimes cheered today,s signature into law ... of 2015 (S.799), which takes much-needed strides ... to drugs, such as opioids, and to improve ... organizations have worked together leading advocacy efforts for ...
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: